We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Zevra Therapeutics (ZVRA - Free Report) shares rallied 21.9% in the last trading session to close at $5.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.2% loss over the past four weeks.
The stock rallied after the FDA indicated that it would convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee to review the company’s new drug application (NDA) for pipeline candidate arimoclomol. The NDA is seeking approval for arimoclomol as an orally delivered, first-in-class treatment for Niemann-Pick disease type C.
This specialty pharmaceutical company is expected to post quarterly loss of $0.45 per share in its upcoming report, which represents a year-over-year change of -200%. Revenues are expected to be $4.41 million, down 48% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Zevra Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ZVRA going forward to see if this recent jump can turn into more strength down the road.
Zevra Therapeutics is part of the Zacks Medical - Drugs industry. Verrica Pharmaceuticals Inc. (VRCA - Free Report) , another stock in the same industry, closed the last trading session 3.8% higher at $7.99. VRCA has returned -10.1% in the past month.
For Verrica Pharmaceuticals, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.43. This represents a change of -104.8% from what the company reported a year ago. Verrica Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
Zevra Therapeutics (ZVRA - Free Report) shares rallied 21.9% in the last trading session to close at $5.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.2% loss over the past four weeks.
The stock rallied after the FDA indicated that it would convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee to review the company’s new drug application (NDA) for pipeline candidate arimoclomol. The NDA is seeking approval for arimoclomol as an orally delivered, first-in-class treatment for Niemann-Pick disease type C.
This specialty pharmaceutical company is expected to post quarterly loss of $0.45 per share in its upcoming report, which represents a year-over-year change of -200%. Revenues are expected to be $4.41 million, down 48% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Zevra Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ZVRA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Zevra Therapeutics is part of the Zacks Medical - Drugs industry. Verrica Pharmaceuticals Inc. (VRCA - Free Report) , another stock in the same industry, closed the last trading session 3.8% higher at $7.99. VRCA has returned -10.1% in the past month.
For Verrica Pharmaceuticals, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.43. This represents a change of -104.8% from what the company reported a year ago. Verrica Pharmaceuticals currently has a Zacks Rank of #3 (Hold).